Mr. Oren Shuster reports

IM CANNABIS ANNOUNCES CHANGE OF AUDITORS

IM Cannabis Corp. has changed its auditor from Kost Forer Gabbay & Kasierer, a member of Ernst & Young Global, to Fahn Kanne & Co. Grant Thornton Israel, effective Jan. 16, 2025. The predecessor auditor resigned effective Jan. 16, 2025, at the company's request, and the company's board of directors, upon the audit committee's recommendation, appointed the successor auditor to fill the resulting vacancy until the close of the next annual meeting of the company's shareholders.

The change of auditor notice required pursuant to National Instrument 51-102 -- Continuous Disclosure Obligations, and associated materials have been filed on SEDAR+ under the company's profile within the prescribed time period. There were no reservations or modified opinions in any auditor's reports nor any reportable events, as defined in NI 51-102, in connection with the audits by the predecessor auditor of the company's most recently completed financial year or any subsequent period.

About IM Cannabis Corp.

IM Cannabis is an international cannabis company that provides premium cannabis products to medical patients in Israel and Germany, two of the largest medical cannabis markets. The company has focused its resources to achieve sustainable and profitable growth in its highest-value markets: Israel and Germany. The company leverages a transnational ecosystem powered by a unique, data-driven approach and a globally sourced product supply chain. With an unwavering commitment to responsible growth and compliance with the strictest regulatory environments, the company strives to amplify its commercial and brand power to become a global high-quality cannabis player.

The IM Cannabis ecosystem operates in Israel through its subsidiaries, which imports and distributes cannabis to medical patients, leveraging years of proprietary data and patient insights. The company also operates medical cannabis retail pharmacies, on-line platforms, distribution centres and logistical hubs in Israel that enable the safe delivery and quality control of IM Cannabis products throughout the entire value chain. In Germany, the IM Cannabis ecosystem operates through Adjupharm GmbH, where it distributes cannabis to pharmacies for medical cannabis patients.

We seek Safe Harbor.